Patient with osseous metastatic prostatic cancer can clinically be detected by bone scanning, which usually is sensitive and qualitative but is not specific and quantitative. For quantitative evaluation of skeletal lesions, we measured bone mineral density (BMD) in whole body, total spine and lumbar spine. All patients also were assessed with bone radiography, radionuclide bone scan, prostate specific antigen (PSA), and prostatic acid phosphatase (PAP). We compared mainly bone scan and BMD in monitoring tumor response between before hormonal treatment and 6 month after hormonal treatment. Fifteen patients with stage D2 prostate cancer and 25 controls were entered in this study. Of 8 patients whose scan showed response in 12 patients with metastatic lumbar spine lesion, they had either 7 responded or 1 unchanged BMD level in the lumbar spine. Of 9 patients whose scan showed response in 15 patients with metastatic total spine lesion, they had either 6 responded or 3 unchanged BMD level in the total spine. The alterations of BMD levels in total spine and lumbar spine closely correlated with the therapeutic responses assessed by the National Prostatic Cancer Project Criteria of bone scintigraphy in patients with prostatic cancer (spine: r=0.04, p<0.05; lumbar: r=0.1, p<0.05). In contrast, BMD changes in whole body (response rate: 20.0%, P<0.05) was less than that in total spin (response rate: 53.3%, P<0.01) and lumbar spine (response rate: 58.3%, P<0.01). In conclusion, when compare BMD to the hot spot region in bone scan, BMD may be helpful to the urologist for the accuracy of the staging and evaluation of the treatment response to androgen deprivation therapy in metastatic prostate cancer.
Acid Phosphatase ; Bone Density ; Densitometry* ; Evaluation Studies as Topic ; Humans ; Prostate-Specific Antigen ; Prostatic Neoplasms* ; Radiography ; Radionuclide Imaging ; Spine

Purpose: The incidence of choledochal cyst (CC) with protein plugs is between 15.5%–40.4%. However, studies on CCs with protein plugs in children are limited. We aimed to analyze the clinical features, surgical findings, and complications of pediatric CCs with and without protein plugs. Methods: We retrospectively analyzed 390 patients who underwent surgery for CCs between January 1987 and September 2017. The patients were divided into 2 groups: groups A (CC with protein plugs) and B (CC without protein plugs). The presence of protein plugs was evaluated using preoperative images or identified during surgery. Results: One hundred forty-two (36.4%) patients had protein plugs in the pancreaticobiliary duct. The most common initial clinical presentation was abdominal pain, and its incidence was significantly higher in group A (66.2%) than in group B (54.8%) (P = 0.032). The incidence of accompanying pancreatitis was also significantly higher in group A (37.3% vs. 27.0%) (P = 0.040). Anomalous pancreaticobiliary ductal union (APBDU) was found in 261 patients (66.9%) and its incidence was significantly higher in group A (74.6% vs. 62.5%) (P = 0.014). Most protein plugs were found in the cyst (88.0%) and common channel (31.7%).The incidence of early complications was higher in group A; conversely, that of late complications did not differ. Conclusion Approximately 36.4% of the pediatric CC patients were accompanied by protein plugs. Abdominal pain, pancreatitis, and APBDU were more commonly observed among those with protein plugs than among those without; longterm complications did not differ between them.

BACKGROUND: Anterior cerebral artery (ACA) flow abnormalities on a transcranial Doppler ultrasonography (TCD) represent various conditions, which include hyperemic collateral to the ipsilateral middle cerebral artery (iMCA) or contralateral internal carotid artery (cICA) pathology, and ipsilateral anterior cerebral artery (iACA) stenosis. However, studies related to these conditions have rarely been done. We evaluated the hemodynamic significance of ACA flow abnormalities on TCD without angiographic information. METHODS: We analyzed TCD records, which were recruited consecutively during a 10-month period in our laboratory. ACA abnormalities on TCD were defined as follows: 1) mean flow velocities (mFV) of ACA>80 cm/sec; 2) ipsilateral mFV ACA/MCA> 1.2; 3) anterior cerebral artery veloci-ty ratios (ACAVR)> 1.34. We then correlated TCD patterns with a magnetic resonance angiography (MRA) or trans-femoral cerebral angiography (TFCA). RESULTS: Thirty-five patients were recruited to participate in this study. Based on MRA or TFCA, we found 4 patterns of vascular status which could explain the ACA abnormalities on the TCD. The iMCA pathology was demonstrated in 14 cases, cICA pathology in 11 cases, iACA stenosis in 3 cases, and cACA hypoplasia in 5 cases. Eight cases did not show any vascular pathology. CONCLUSIONS: ACA flow abnormalities should be evaluated with absolute flow velocity indicies, as well as other indexes, which mostly signify hyperemic collateral flow to the iMCA or cICA steno-occlusion. (J Korean Neurol Assoc 19(4):349~353, 2001)
Angiography ; Anterior Cerebral Artery* ; Carotid Artery, Internal ; Cerebral Angiography ; Constriction, Pathologic ; Hemodynamics ; Humans ; Magnetic Resonance Angiography ; Middle Cerebral Artery ; Pathology ; Ultrasonography, Doppler, Transcranial*

Mitochondrial neurogastrointestinal encephalomyopahty (MNGIE) is a rare disorder and is clinically characterized by ophthalmoparesis, peripheral neuropathy, leukoencephalopathy, gastrointestinal symptoms with intestinal dysmotility, and histologically abnormal mitochondria in muscle. A 32-year-old female showed external ophthalmoparesis, bilateral ptosis, quadriparesis, and sensory change below both ankle joints. Level of serum lactic acid was highly increased. The brain MRI showed diffusely increased signal intensity in the centrum semiovale and white matter. Electron microscopic finding showed paracrystalline inclusions in mitochondria of a few muscle fibers. (J Korean Neurol Assoc 19(3):309~312, 2001)
Adult ; Ankle Joint ; Brain ; Female ; Humans ; Lactic Acid ; Leukoencephalopathies ; Magnetic Resonance Imaging ; Mitochondria ; Mitochondrial Encephalomyopathies ; Ophthalmoplegia ; Peripheral Nervous System Diseases ; Quadriplegia

Objective: We conducted this study to examine the characteristics of dog-bite injuries and to analyze the factors affecting hospitalization in a single-center emergency department (ED) setting in Korea. Methods: The current single-center, retrospective, cohort study was conducted on 202 patients with dog-bite injuries who visited our medical institution between 2011 and 2019 through a retrospective analysis of their medical records. Results: The Pearson’s chi-square test indicated that outpatient treatment had a significant positive correlation with the location of the bite. Also, hospitalization had a significant positive correlation with age and the depth of the bite wounds (P=0.002, P=0.031, and P=0.034, respectively). On multiple regression analysis, it was observed that hospitalization had a significant positive correlation with age (odds ratio [OR], 1.421; 95% confidence interval [CI], 1.047-1.529; P=0.011) and the depth of the bite wounds (OR, 1.077; 95% CI, 1.013-1.139; P=0.014). Conclusion In conclusion, our results indicate that older patients and those with deeper bite wounds are vulnerable to hospitalization. This would be helpful in an ED setting for dispensing treatment to those with dog-bite injuries.

Purpose: The standard care for patients with ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery (BCS) is a total mastectomy (TM); however, there is growing interest in repeating BCS for IBTR. Methods: We retrospectively analyzed patients with IBTR who underwent initial BCS for breast cancer at our institution between January 2000 and December 2018. The Kaplan-Meier method was used to compare survival rates between the standard BCS-TM treatment group and the repeat-BCS group. Results: We enrolled 209 IBTR patients with a median follow-up of 102.3 months. No significant differences were observed in overall survival (10 years: 87.3% vs. 78.8%; hazard ratio [HR], 1.11; 95% confidence interval [CI], 0.44-2.81; p=0.821), distant metastasis free survival (10 years: 73.9% vs. 77.7%; HR, 0.80; 95% CI, 0.37-1.72; p=0.727) and disease-free survival (10 years: 57.1% vs. 65.2%; HR, 0.63; 95% CI, 0.35-1.12; p=0.115) between two groups. Repeat-BCS group showed significantly poorer locoregional recurrence free survival rate than did the TM group (HR, 2.44; 95% CI, 1.06-5.56; p=0.029) but the significance was not shown after excluding ipsilateral breast tumor recurrence events. Conclusion No significant differences were observed in survival outcomes and recurrence rates between patients with IBTR who underwent mastectomy or repeat BCS regardless of molecular subtype, except secondary IBTR rates.

Purpose: Trastuzumab is effective in early and advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, few studies have reported the effect of trastuzumab on ipsilateral breast tumor recurrence (IBTR), whose incidence is higher in the HER2-positive subtype than in other subtypes. Methods: We retrospectively investigated 959 patients who underwent breast-conserving surgery (BCS), chemotherapy, and radiotherapy for HER2-positive breast cancer between 2000 and 2017. IBTR was compared between the patients who received neoadjuvant or adjuvant trastuzumab (Tmab group) for a total duration of 1 year and those who received no trastuzumab (N-Tmab group). Results: Propensity score matching designated 426 and 142 patients in the Tmab and N-Tmab groups, respectively. The median follow-up period for all patients after matching was 73.79 months. The IBTR-free survival rate was significantly higher in the Tmab group than in the N-Tmab group (10-year IBTR-free survival rate, 92.9% vs. 87.3%; p = 0.002). The multivariate analysis showed a significant association between the N-Tmab and Tmab group (hazard ratio, 3.03; 95% confidence interval, 1.07–8.59) and IBTR in addition to close or positive resection margin and hormone receptor (HR) positivity. The subgroup analysis showed that adjuvant treatment with trastuzumab significantly reduced IBTR among the patients with HR-negative or lymph node-negative breast cancer. Conclusion Significantly reduced IBTR after BCS was observed in the patients who received 1 year of adjuvanteoadjuvant trastuzumab treatment for HER2-positive breast cancer.

Purpose: Trastuzumab is effective in early and advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer. However, few studies have reported the effect of trastuzumab on ipsilateral breast tumor recurrence (IBTR), whose incidence is higher in the HER2-positive subtype than in other subtypes. Methods: We retrospectively investigated 959 patients who underwent breast-conserving surgery (BCS), chemotherapy, and radiotherapy for HER2-positive breast cancer between 2000 and 2017. IBTR was compared between the patients who received neoadjuvant or adjuvant trastuzumab (Tmab group) for a total duration of 1 year and those who received no trastuzumab (N-Tmab group). Results: Propensity score matching designated 426 and 142 patients in the Tmab and N-Tmab groups, respectively. The median follow-up period for all patients after matching was 73.79 months. The IBTR-free survival rate was significantly higher in the Tmab group than in the N-Tmab group (10-year IBTR-free survival rate, 92.9% vs. 87.3%; p = 0.002). The multivariate analysis showed a significant association between the N-Tmab and Tmab group (hazard ratio, 3.03; 95% confidence interval, 1.07–8.59) and IBTR in addition to close or positive resection margin and hormone receptor (HR) positivity. The subgroup analysis showed that adjuvant treatment with trastuzumab significantly reduced IBTR among the patients with HR-negative or lymph node-negative breast cancer. Conclusion Significantly reduced IBTR after BCS was observed in the patients who received 1 year of adjuvanteoadjuvant trastuzumab treatment for HER2-positive breast cancer.

Purpose: Patients with breast cancer with positive lumpectomy margins have a two-fold increased risk of ipsilateral breast tumor recurrence (IBTR). This can be the result of either technically incomplete resection or the biological characteristics of the tumor that lead to a positive margin. We hypothesized that if achieving negative margins by re-excision nullifies the IBTR risk, then the increased risk is mainly attributed to the technical incompleteness of the initial surgeries. Thus, we investigated IBTR rates in patients with breast cancer who achieved clear margins after re-excision. Methods: We retrospectively reviewed patients who underwent breast lumpectomy for invasive breast cancer between 2004 and 2018 at a single institution, and investigated IBTR events. Results: Among 5,598 patients, 793 achieved clear margins after re-excision of their initial positive margins. During the median follow-up period of 76.4 months, 121 (2.2%) patients experienced IBTR. Patients who underwent re-excision to achieve negative margin experienced significantly higher IBTR rates compared to those achieving clear margin at first lumpectomy (10-year IBTR rate: 5.3% vs. 2.6% [25 vs. 84 events]; unadjusted p = 0.031, hazard ratio, 1.61, 95% confidence interval [CI], 1.04–2.48; adjusted p = 0.030, hazard ratio, 1.69, 95% CI, 1.05–2.72). This difference was more evident in patients aged < 50 years and those with delayed IBTR. Additionally, no statistically significant differences were observed in the spatial distribution of IBTR locations. Conclusion Patients who underwent re-excision for initial positive margins had an increased risk of IBTR, even after achieving a final negative margin, compared to patients with negative margins initially. This increased risk of IBTR is mostly observed in young patients and delayed cases.

Purpose: In this study, we investigated the prognostic implications of focal breast edema on preoperative breast magnetic resonance imaging (MRI) in patients with breast cancer. Methods: Data of 899 patients with breast cancer at a single institution were retrospectively analyzed. The patients were divided into an edema-positive group (EPG) and an edemanegative group (ENG) based on the presence of peritumoral, prepectoral, or subcutaneous edema. Two radiologists evaluated the presence or absence of focal edema and its subtypes on preoperative breast MRI. Clinicopathologic characteristics and survival outcomes were compared between the two groups and among the three subtypes using Pearson’s χ2 test, Kaplan–Meier estimator, and Cox proportional hazards model. Results: There were 399 (44.4%) and 500 (55.6%) patients in the EPG and ENG, respectively.The EPG showed significantly higher rates of axillary lymph node metastasis (55.6% vs.19.2%, p < 0.001) and lymphovascular invasion (LVI) (57.9% vs. 12.6%, p < 0.001) than the ENG. Patients in the EPG showed significantly worse overall survival (OS) rate (log-rank p < 0.001; hazard ratio [HR], 4.83; 95% confidence interval [CI], 2.56–9.11) and recurrencefree survival rate (log-rank p < 0.001; HR, 3.00; 95% CI, 1.94–4.63) than those in the ENG.After adjusting for other variables, focal breast edema remained a significant factor affecting the OS rate, regardless of the edema type. Specifically, the presence of subcutaneous edema emerged as the strongest predictor for OS with the highest HR (p < 0.001; HR, 9.10; 95% CI, 3.05–27.15). Conclusion Focal breast edema on preoperative breast MRI implies a higher possibility of LVI and axillary lymph node metastasis, which can lead to a poor prognosis. A detailed description of focal breast edema, especially subcutaneous edema, on preoperative breast MRI may provide prognostic predictions. More intensive surveillance is required for patients with breast cancer and focal preoperative breast edema.